IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by CX Institutional

CX Institutional reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 25.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,176 shares of the medical research company’s stock after selling 395 shares during the period. CX Institutional’s holdings in IQVIA were worth $231,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Brighton Jones LLC boosted its stake in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the last quarter. Mutual Advisors LLC lifted its holdings in shares of IQVIA by 14.8% during the 4th quarter. Mutual Advisors LLC now owns 1,689 shares of the medical research company’s stock worth $334,000 after acquiring an additional 218 shares during the period. Janney Montgomery Scott LLC lifted its holdings in shares of IQVIA by 3.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 36,512 shares of the medical research company’s stock worth $7,175,000 after acquiring an additional 1,172 shares during the period. Advisory Alpha LLC lifted its holdings in shares of IQVIA by 18.2% during the 4th quarter. Advisory Alpha LLC now owns 3,189 shares of the medical research company’s stock worth $627,000 after acquiring an additional 492 shares during the period. Finally, Howard Capital Management Group LLC lifted its holdings in shares of IQVIA by 1.5% during the 4th quarter. Howard Capital Management Group LLC now owns 121,894 shares of the medical research company’s stock worth $23,953,000 after acquiring an additional 1,860 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Bank of America cut their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Barclays cut their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Evercore ISI cut their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, Leerink Partners restated an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $255.71.

IQVIA Stock Down 0.7 %

IQV stock opened at $204.54 on Monday. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $37.12 billion, a P/E ratio of 26.84, a PEG ratio of 2.14 and a beta of 1.48. The firm has a 50 day simple moving average of $199.71 and a 200-day simple moving average of $221.11.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.